Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

To diagnose Polycystic Ovarian Syndrome, two out of three signs—irregular periods, high male hormone levels, or cysts on the ovaries—are needed.

In this study using zebrafish, four bisbenzylisoquinoline derivatives were found to protect hair cells from aminoglycoside-induced damage without reducing antibiotic efficacy, potentially leading to therapies for patients undergoing such treatments.

This review examines the role of regulatory T cells in skin immune disorders, highlighting their unique functions in conditions like scleroderma, alopecia areata, and psoriasis, without reporting new clinical results.

This study suggests that women with polycystic ovary syndrome may have a distinct metabolomic profile, differing in levels of amino acids, organic acids, and lipids compared to controls.

This study found that insulin resistance was significantly associated with PCOS among infertile women with central obesity, highlighting differences in insulin and phenotype severity.

This study found that women with PCOS who have an exaggerated 17-hydroxyprogesterone response to buserelin exhibit more severe hyperandrogenemia, increased insulin secretion, and reduced insulin sensitivity.

This review suggests that quercetin supplementation may benefit ovarian functions and hormonal levels in polycystic ovary syndrome, though further high-quality trials are needed for confirmation.

This study found that micrografts containing human hair follicle mesenchymal stem cells significantly increased hair count and density compared to placebo over 58 weeks in patients experiencing hair loss.

This paper reviews hair structure and damage from grooming and cosmetic exposure but reports no new clinical findings; it suggests collaboration between dermatologists and cosmetic chemists to improve hair care products.

This article explains the structure and multifunctional roles of the human skin, including its protective, regulatory, and sensory functions, but does not report new research findings.

This article discusses diagnostic guidelines for PCOS, emphasizing the use of the Rotterdam criteria and recommending clomiphene citrate as the first-line treatment for ovulation induction; it reports no new clinical results.

In this study, treatment with insulin sensitizers significantly increased adipose tissue GLUT4 mRNA expression and improved insulin resistance, menstrual patterns, and androgen profiles in PCOS patients, with rosiglitazone being more effective than metformin.

This study suggests that although the G972R variant of the IRS1 gene might increase AA excess risk in heterozygous carriers with CYP21 mutations, both variations play a limited role in PCOS development.

This study found that specific SHBG gene variants, rs727428 and rs6259, were associated with PCOS in Mediterranean women, although the associations were relatively weak and do not indicate a causative role.

This article reviews evidence on hyperinsulinemia and insulin resistance in women with polycystic ovary syndrome and evaluates therapeutic responses to insulin-lowering agents, reporting no new clinical findings.

In this study, socially defeated mice showed increased alcohol consumption, and CRF-R1 antagonism selectively reduced drinking in these mice, suggesting a potential treatment target for stress-related alcohol use disorders.

This study found that serum vaspin levels were elevated in women with polycystic ovary syndrome compared to controls, but treatment with metformin or weight loss did not significantly change these levels.

This study reported that women with PCOS had higher levels of certain hormones and lower SHBG levels compared to non-PCOS women with similar symptoms, highlighting a less favorable endocrine profile in PCOS cases.

This review discusses the challenges of using surrogate variables versus primary clinical end-points in PCOS trials and reports no new research results; the authors suggest focusing future studies on primary outcomes.

This review summarizes current knowledge on the efficacy of natural molecule supplementation, such as inositols and omega-3 fatty acids, in managing PCOS symptoms but reports no new clinical results.

This narrative review discusses the structure and functions of the skin, focusing on its barrier role, self-repair, thermoregulation, and immune functions, and reports no new experimental results.

This study reported that almost 25% of women with PCOS were diagnosed with NAFLD, and 32.7% to 44.6% had metabolic syndrome, with higher prevalence in those with both conditions.

Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.

This review discusses the known morbidities of polycystic ovarian syndrome, highlighting its diverse impacts on women's health, but reports no new research findings.

This review summarizes various treatment options for polycystic ovary syndrome, noting that while some treatments address specific symptoms, no single therapy fully resolves the condition.

This review discusses normal menstrual variations and common menstrual disorders in adolescent girls, focusing on symptoms, evaluation, and management, but does not present new clinical results.

Metformin improves menstrual cycles and hormone levels in women with PCOS, mostly within the first 6 months.

In this study, elevated afamin concentrations were associated with metabolic syndrome in young women, particularly those with insulin resistance, suggesting a potential predictive role for afamin in metabolic risk assessment.

This study found that among women above 15 years with acne, 54.56% exhibited hyperandrogenism, with dehydroepiandrosterone sulfate levels most frequently elevated.

This review describes the clinical evaluation and management options for women with polycystic ovary syndrome, focusing on its endocrine and metabolic implications, but reports no new results.